Markets:

Overview

News

Currencies

International

Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

32.88 +0.34 (+1.04%)

Streaming Delayed Price Updated: 2:43 PM EDT, Sep 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

January 25, 2024

From Vera Therapeutics

Via GlobeNewswire

Why Vera Therapeutics Stock Soared by 22% This Week ↗

January 12, 2024

Executive changes and a bullish analyst take combined to boost sentiment on the company.

Via The Motley Fool

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

January 08, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

January 08, 2024

From Vera Therapeutics

Via GlobeNewswire

Recap: Vera Therapeutics Q3 Earnings ↗

November 09, 2023

Via Benzinga

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 27, 2023

From Vera Therapeutics

Via GlobeNewswire

Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗

December 21, 2023

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...

Via Benzinga

Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst ↗

December 18, 2023

Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion...

Via Benzinga

This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street ↗

December 15, 2023

Is the stock's risk worth the potential reward?

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 20, 2023

Via Benzinga

Synaptics To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 10, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

November 09, 2023

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

November 04, 2023

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Scheduled to Present at November Investor Conferences

October 30, 2023

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

October 13, 2023

From Vera Therapeutics

Via GlobeNewswire

Why Shares of Vera Therapeutics Jumped Tuesday ↗

September 26, 2023

The stock bounced back Tuesday from a three-month low it hit on Monday.

Via The Motley Fool

Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 26, 2023

Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi...

Via Benzinga

Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗

September 26, 2023

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Vera Therapeutics Scheduled to Present at September Investor Conferences

August 31, 2023

From Vera Therapeutics

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023 ↗

August 16, 2023

Via Benzinga

Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

August 10, 2023

From Vera Therapeutics

Via GlobeNewswire

Around $8.5M Bet On Eagle Bulk Shipping? Check Out These 4 Stocks Insiders Are Buying ↗

June 23, 2023

Although US stocks closed mostly higher on Thursday, there were a few notable insider trades.

Via Benzinga

Why Shares of Vera Therapeutics Jumped Tuesday ↗

June 20, 2023

The company announced early phase 2 trials information regarding its lead therapy.

Via The Motley Fool

Vera Therapeutics Stock Is Trading Higher Today - Here's Why ↗

June 20, 2023

On Saturday, Vera Therapeutics Inc (NASDAQ: VERA) announced that the Phase 2b ORIGIN trial of atacicept for the treatment of IgA nephropathy (IgAN) met its primary and key secondary endpoints, with...

Via Benzinga

DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday ↗

June 20, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

2 Surging Healthcare Stocks With More Fuel in the Tank ↗

June 20, 2023

These stocks climbed 74% and 78% over the past month and there could be more gains ahead.

Via The Motley Fool

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

June 17, 2023

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN

June 15, 2023

From Vera Therapeutics

Via GlobeNewswire

Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 15, 2023

Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 14, 2023

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.